Antonio Cristóbal Luque Ambrosiani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Cristóbal Luque Ambrosiani has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Astrid Adarmes‐Gómez
Unidad de Trastornos del Movimiento, Servicio de Neurología Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/Universidad de Sevilla Sevilla Spain
2 shared publicationsDaniel Macías‐García
Unidad de Trastornos del Movimiento, Servicio de Neurología Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/Universidad de Sevilla Sevilla Spain
2 shared publications- Elena Ojeda-Lepe
Unidad de Trastornos del Movimiento, Servicio de Neurología Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/Universidad de Sevilla Sevilla Spain
2 shared publications Fátima Carrillo‐García
Unidad de Trastornos del Movimiento, Servicio de Neurología Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/Universidad de Sevilla Sevilla Spain
2 shared publications- Laura Muñoz-Delgado
Unidad de Trastornos del Movimiento, Servicio de Neurología Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/Universidad de Sevilla Sevilla Spain
2 shared publications - Miguel Martín‐Bórnez
Unidad de Trastornos del Movimiento, Servicio de Neurología Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen Del Rocío/Universidad de Sevilla Sevilla Spain
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Movement Disorders
Cross‐Cohort Evidence Links KCNJ6 rs702859 to Impulsive–Compulsive Phenotypes in Parkinson's Disease
Background: Impulse control disorders (ICDs) and related compulsive behaviors (CBs) are frequent non‐motor complications of Parkinson's disease (PD) with a probable genetic contribution. Objective: To investigate whether genetic variants involved in reward and punishment processing are associated with impulsive–compulsive phenotypes in PD. Methods: We analyzed a cross‐sectional Seville cohort (N = 449) and an independent Parkinson's Progression Markers Initiative (PPMI) cohort (N = 433) with longitudinally collected assessments. ICDs and CBs were assessed with the full QUIP (Questionnaire for Impulsive‐Compulsive Disorders in Parkinson’s Disease) in Seville and the short form (QUIP‐S) in PPMI. Dopaminergic exposure was quantified as levodopa‐ and dopamine agonist‐equivalent daily doses. A candidate‐variant panel selected through systematic review was evaluated using covariate‐adjusted case–control analyses with empirical P ‐values from 5000 permutations, followed by random‐effects meta‐analysis, exploratory genotype‐by‐treatment analyses, and in silico functional annotation. Results: rs702859, a synonymous KCNJ6 variant, was associated with CBs in Seville (odds ratio [OR] 1.46; 95% confidence interval [CI] 1.02–2.09) and with ICDs in PPMI (OR 1.56; 95% CI 1.11–2.19). Meta‐analysis supported an association with ICDs (pooled OR 1.36; 95% CI 1.03–1.80). Exploratory analyses showed nominal interactions between rs702859 and dopamine agonist dose in Seville that were not reproduced in PPMI. rs702859 was in strong linkage disequilibrium with rs146589674, a KCNJ6 3′ untranslated region variant; expression, chromatin accessibility, and methylation quantitative trait loci (QTL) data linked risk alleles to reduced KCNJ6 expression. Conclusions: KCNJ6 rs702859 showed convergent variant‐level associations across related impulsive–compulsive phenotypes in two independent cohorts, supporting further investigation of KCNJ6 ‐related pathways. Independent functional and clinical validation is required. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 21 October 2026
- Published by Wiley in Movement Disorders
Open AccessCross‐Cohort Evidence Links KCNJ6 rs702859 to Impulsive–Compulsive Phenotypes in Parkinson's Disease
Background: Impulse control disorders (ICDs) and related compulsive behaviors (CBs) are frequent non‐motor complications of Parkinson's disease (PD) with a probable genetic contribution. Objective: To investigate whether genetic variants involved in reward and punishment processing are associated with impulsive–compulsive phenotypes in PD. Methods: We analyzed a cross‐sectional Seville cohort (N = 449) and an independent Parkinson's Progression Markers Initiative (PPMI) cohort (N = 433) with longitudinally collected assessments. ICDs and CBs were assessed with the full QUIP (Questionnaire for Impulsive‐Compulsive Disorders in Parkinson’s Disease) in Seville and the short form (QUIP‐S) in PPMI. Dopaminergic exposure was quantified as levodopa‐ and dopamine agonist‐equivalent daily doses. A candidate‐variant panel selected through systematic review was evaluated using covariate‐adjusted case–control analyses with empirical P ‐values from 5000 permutations, followed by random‐effects meta‐analysis, exploratory genotype‐by‐treatment analyses, and in silico functional annotation. Results: rs702859, a synonymous KCNJ6 variant, was associated with CBs in Seville (odds ratio [OR] 1.46; 95% confidence interval [CI] 1.02–2.09) and with ICDs in PPMI (OR 1.56; 95% CI 1.11–2.19). Meta‐analysis supported an association with ICDs (pooled OR 1.36; 95% CI 1.03–1.80). Exploratory analyses showed nominal interactions between rs702859 and dopamine agonist dose in Seville that were not reproduced in PPMI. rs702859 was in strong linkage disequilibrium with rs146589674, a KCNJ6 3′ untranslated region variant; expression, chromatin accessibility, and methylation quantitative trait loci (QTL) data linked risk alleles to reduced KCNJ6 expression. Conclusions: KCNJ6 rs702859 showed convergent variant‐level associations across related impulsive–compulsive phenotypes in two independent cohorts, supporting further investigation of KCNJ6 ‐related pathways. Independent functional and clinical validation is required. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 20 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (10) , 2517-2525
Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease
Background: Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge. One strategy used to maintain stable levodopa plasma levels throughout the day is the use of opicapone, a catechol‐O‐methyltransferase (COMT) inhibitor. Despite its efficacy, there is variability in the therapeutic response and development of adverse events to this drug. Variants in the COMT and UGT1A genes have been proposed to modulate the effect of this medication, either positively or negatively. Objective: To assess the impact of COMT and UGT1A genetic variants on opicapone efficacy in PD patients. Methods: We conducted a retrospective study of 237 PD patients treated with opicapone between May 2017 and June 2025. The COMT rs4818, rs4680, rs4633 and rs6269, and UGT1A rs1105880 SNPs were genotyped. Three established COMT activity haplotypes (low, medium, and high) were evaluated alongside clinical characteristics and treatment response. Results: COMT rs4818 and rs6269 heterozygosity was associated with improvement in motor fluctuations. The low activity COMT haplotype was associated with improved motor fluctuations, whereas the medium activity COMT haplotype showed only a nominal protective association against dyskinesia worsening. The UGT1A rs1105880 dominant model was significantly associated with improvement in motor fluctuations. No variant was associated with treatment discontinuation. Conclusions: These results suggest that COMT and UGT1A genotyping may contribute to personalized therapy in PD , although prospective validation is needed.
- 20 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (10) , 2517-2525
Open AccessEffect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease
Background: Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge. One strategy used to maintain stable levodopa plasma levels throughout the day is the use of opicapone, a catechol‐O‐methyltransferase (COMT) inhibitor. Despite its efficacy, there is variability in the therapeutic response and development of adverse events to this drug. Variants in the COMT and UGT1A genes have been proposed to modulate the effect of this medication, either positively or negatively. Objective: To assess the impact of COMT and UGT1A genetic variants on opicapone efficacy in PD patients. Methods: We conducted a retrospective study of 237 PD patients treated with opicapone between May 2017 and June 2025. The COMT rs4818, rs4680, rs4633 and rs6269, and UGT1A rs1105880 SNPs were genotyped. Three established COMT activity haplotypes (low, medium, and high) were evaluated alongside clinical characteristics and treatment response. Results: COMT rs4818 and rs6269 heterozygosity was associated with improvement in motor fluctuations. The low activity COMT haplotype was associated with improved motor fluctuations, whereas the medium activity COMT haplotype showed only a nominal protective association against dyskinesia worsening. The UGT1A rs1105880 dominant model was significantly associated with improvement in motor fluctuations. No variant was associated with treatment discontinuation. Conclusions: These results suggest that COMT and UGT1A genotyping may contribute to personalized therapy in PD , although prospective validation is needed.
- Open Access
- 3 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 7391-7406
Semiquantitative [¹²³I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of Parkinson’s disease and atypical parkinsonian syndrome
Purpose: To evaluate whether semiquantitative striatal [¹²³I]FP-CIT SPECT-derived metrics improve clinical differentiation of degenerative parkinsonism using an integrated machine learning approach. Methods: This cross-sectional study included 487 patients with Parkinson’s disease (PD) and 219 with atypical parkinsonisms (APS), classified as progressive supranuclear palsy (PSP, n = 127), multiple system atrophy parkinsonian type (MSA-P, n = 37), multiple system atrophy cerebellar type (MSA-C, n = 12), and corticobasal degeneration (CBD, n = 43). All participants underwent a [¹²³I]FP-CIT SPECT. Striatal [¹²³I]FP-CIT uptake was quantified using anatomical (caudate, putamen, ventral striatum) and functional (limbic, executive, sensorimotor) parcellations to calculate specific binding ratios, asymmetry indices, and inter-regional ratios. Discriminative performance of each metric was evaluated using receiver operating characteristic (ROC) curves analyses. A random forest classifier integrating all semiquantitative metrics was trained and validated, enabling data-driven identification diagnostic pathways. Results: Caudate-to-putamen and sensorimotor-to-limbic inter-regional ratios showed the strongest discriminative performance (AUC up to 0.95) for differentiating PD from APS. The random forest achieved a 64% overall accuracy with high per-class specificities (> 84%) and revealed two diagnostic pathways. A lower caudate-to-posterior putamen ratio, primarily grouped PSP, CBD and MSA-C, where lower contralateral sensorimotor uptake pointing to PSP while higher values and ipsilateral caudate uptake subregion further distinguishing CBD from MSA-C. A higher caudate-to-posterior putamen ratio, included PD and MSA-P, where lower ipsilateral caudate uptake together with a higher sensorimotor-to-cognitive ratio mainly differentiate both groups. Conclusions: Integrating anatomical and functional [¹²³I]FP-CIT SPECT metrics within a machine learning framework enhances the clinical differentiation of degenerative parkinsonisms and supports [¹²³I]FP-CIT SPECT as a robust in vivo disease biomarker.
- 3 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 7391-7406
Open AccessSemiquantitative [¹²³I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of Parkinson’s disease and atypical parkinsonian syndrome
Purpose: To evaluate whether semiquantitative striatal [¹²³I]FP-CIT SPECT-derived metrics improve clinical differentiation of degenerative parkinsonism using an integrated machine learning approach. Methods: This cross-sectional study included 487 patients with Parkinson’s disease (PD) and 219 with atypical parkinsonisms (APS), classified as progressive supranuclear palsy (PSP, n = 127), multiple system atrophy parkinsonian type (MSA-P, n = 37), multiple system atrophy cerebellar type (MSA-C, n = 12), and corticobasal degeneration (CBD, n = 43). All participants underwent a [¹²³I]FP-CIT SPECT. Striatal [¹²³I]FP-CIT uptake was quantified using anatomical (caudate, putamen, ventral striatum) and functional (limbic, executive, sensorimotor) parcellations to calculate specific binding ratios, asymmetry indices, and inter-regional ratios. Discriminative performance of each metric was evaluated using receiver operating characteristic (ROC) curves analyses. A random forest classifier integrating all semiquantitative metrics was trained and validated, enabling data-driven identification diagnostic pathways. Results: Caudate-to-putamen and sensorimotor-to-limbic inter-regional ratios showed the strongest discriminative performance (AUC up to 0.95) for differentiating PD from APS. The random forest achieved a 64% overall accuracy with high per-class specificities (> 84%) and revealed two diagnostic pathways. A lower caudate-to-posterior putamen ratio, primarily grouped PSP, CBD and MSA-C, where lower contralateral sensorimotor uptake pointing to PSP while higher values and ipsilateral caudate uptake subregion further distinguishing CBD from MSA-C. A higher caudate-to-posterior putamen ratio, included PD and MSA-P, where lower ipsilateral caudate uptake together with a higher sensorimotor-to-cognitive ratio mainly differentiate both groups. Conclusions: Integrating anatomical and functional [¹²³I]FP-CIT SPECT metrics within a machine learning framework enhances the clinical differentiation of degenerative parkinsonisms and supports [¹²³I]FP-CIT SPECT as a robust in vivo disease biomarker.
- Open Access
- 26 September 2025
- Published by IMR Press in Revista De Neurologia
- Vol. 80 (8) , 36787
West Nile Virus Neuroinvasive Disease: A Retrospective Analysis of Hospitalized Cases in a Tertiary Care Center in Southern Europe
Background: West Nile virus (WNV) is a flavivirus primarily transmitted by mosquitoes of the Culex genus and is endemic to Southern Europe. Although infection is usually asymptomatic, it can lead to neuroinvasive syndromes with high morbidity and mortality. Due to the increasing incidence driven by climatic factors, we present a single-center series examining short- and long-term functional outcomes after infection. Methods: Patients with neurological symptoms and confirmed WNV infection through serology and/or detection in urine and/or cerebrospinal fluid (CSF) between 2017 and 2023 were included. Data on demographics, medical history, symptoms, diagnostic workup, treatment, and prognosis at discharge, 12 months, and 24 months were analyzed. Patients were categorized based on whether they required intensive care unit (ICU) admission, CSF biochemistry, and treatment employed, among other factors. Results: Forty patients with a median age of 65 years (45% female) were included; 8% were immunosuppressed. Fever was present in 95%, and 85% experienced prodromal symptoms. Altered consciousness (73%) was the most common neurological symptom. ICU admission was required in 33% of cases, and mechanical ventilation in 25%. In-hospital mortality was 15%. At 24 months, 48% maintained good functional status, with a median follow-up of 35 months. Diagnostic and therapeutic interventions did not influence prognosis. Conclusions: Although neuroinvasive WNV disease is rare, it carries significant morbidity and mortality, with no specific therapeutic measures impacting outcomes. Prioritizing efforts to control infection spread is critical.
- 26 September 2025
- Published by IMR Press in Revista De Neurologia
- Vol. 80 (8) , 36787
Open AccessWest Nile Virus Neuroinvasive Disease: A Retrospective Analysis of Hospitalized Cases in a Tertiary Care Center in Southern Europe
Background: West Nile virus (WNV) is a flavivirus primarily transmitted by mosquitoes of the Culex genus and is endemic to Southern Europe. Although infection is usually asymptomatic, it can lead to neuroinvasive syndromes with high morbidity and mortality. Due to the increasing incidence driven by climatic factors, we present a single-center series examining short- and long-term functional outcomes after infection. Methods: Patients with neurological symptoms and confirmed WNV infection through serology and/or detection in urine and/or cerebrospinal fluid (CSF) between 2017 and 2023 were included. Data on demographics, medical history, symptoms, diagnostic workup, treatment, and prognosis at discharge, 12 months, and 24 months were analyzed. Patients were categorized based on whether they required intensive care unit (ICU) admission, CSF biochemistry, and treatment employed, among other factors. Results: Forty patients with a median age of 65 years (45% female) were included; 8% were immunosuppressed. Fever was present in 95%, and 85% experienced prodromal symptoms. Altered consciousness (73%) was the most common neurological symptom. ICU admission was required in 33% of cases, and mechanical ventilation in 25%. In-hospital mortality was 15%. At 24 months, 48% maintained good functional status, with a median follow-up of 35 months. Diagnostic and therapeutic interventions did not influence prognosis. Conclusions: Although neuroinvasive WNV disease is rare, it carries significant morbidity and mortality, with no specific therapeutic measures impacting outcomes. Prioritizing efforts to control infection spread is critical.
- 26 June 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (6) , e264904
Metronidazole-induced toxicity of the central and peripheral nervous system
A woman in her 80s was admitted with a growing feeling of dizziness, tingling and vomiting that began a week before. The neurological examination showed dysarthria, downbeat nystagmus and gait ataxia. At the time, she was taking antibiotics (1 g amoxicillin and 500 mg metronidazole every 8 hours) following surgery for a mandibular abscess a month earlier. Brain MRI showed T2 and FLAIR hyperintensities in dentate nuclei and splenium of the corpus callosum, findings described in metronidazole neurotoxicity. Metronidazole was discontinued, with resolution of all symptoms except lower limb paraesthesias. Given the ageing population and the increasing use of pharmacological treatments for multiple conditions, drug-induced neurological complications are receiving growing attention, yet they often remain underrecognised. Metronidazole neurotoxicity is a rare adverse effect that should be considered especially during prolonged treatments. The most frequent debut resembles this case, with cerebellar dysfunction as the most common central nervous system toxicity and concomitant polyneuropathy frequently associated.
- 26 June 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (6) , e264904
Metronidazole-induced toxicity of the central and peripheral nervous system
A woman in her 80s was admitted with a growing feeling of dizziness, tingling and vomiting that began a week before. The neurological examination showed dysarthria, downbeat nystagmus and gait ataxia. At the time, she was taking antibiotics (1 g amoxicillin and 500 mg metronidazole every 8 hours) following surgery for a mandibular abscess a month earlier. Brain MRI showed T2 and FLAIR hyperintensities in dentate nuclei and splenium of the corpus callosum, findings described in metronidazole neurotoxicity. Metronidazole was discontinued, with resolution of all symptoms except lower limb paraesthesias. Given the ageing population and the increasing use of pharmacological treatments for multiple conditions, drug-induced neurological complications are receiving growing attention, yet they often remain underrecognised. Metronidazole neurotoxicity is a rare adverse effect that should be considered especially during prolonged treatments. The most frequent debut resembles this case, with cerebellar dysfunction as the most common central nervous system toxicity and concomitant polyneuropathy frequently associated.